Biosense Webster launches new ‘Power to Heal’ campaign to alleviate AF burden

New campaign demonstrates commitment to treating the new millennium epidemic of Atrial Fibrillation

Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation, is launching its ‘Power to Heal’ campaign across Europe, the Middle East and Africa at the European Heart Rhythm Association (EHRA) Congress 2018. The campaign reflects the company’s ongoing dedication and mission to cure Atrial Fibrillation and alleviate the burden of disease reoccurrence.

Atrial Fibrillation can have life-altering consequences for patients, increasing a patient’s risk of stroke five-fold and mortality two-fold. It is fast becoming one of the world’s most significant health issues – affecting 14 million people across Europe, the Middle East and Africa, as well as placing a critical burden on healthcare systems with up to 2.5% of total healthcare expenditure associated with the disease.

Despite the significant socio-economic burden associated with the condition, management of Atrial Fibrillation is not optimal. Existing antiarrhythmic drug therapies alone are not well managed for almost half of patients and just 4% of eligible patients receive ablation to treat the condition. Patients often go under-diagnosed and/or are referred too late, when they could instead have access to ablation treatment with success rates reported as high as 92%, as demonstrated with CARTO VISITAG^™ Module with Ablation Index.

“I’m pleased to say that for over 20 years Biosense Webster has pioneered the development of Atrial Fibrillation ablation treatment and through working closely with healthcare professionals have been able to give thousands of patients their lives back” said Gabriele Fischetto, Vice President of Johnson & Johnson Cardiovascular Specialty Solutions in EMEA “but – there are still thousands who are yet to enjoy their lives once again. These patients are our driving force. Through continued partnership and collaboration, we believe that we will be able to power positive outcomes for the benefit of patients, providers and healthcare systems. Together, we have the Power to Heal”.

The Power to Heal campaign, launched at the EHRA Congress, is in direct response to this growing epidemic, where Biosense Webster is hosting a series of educational events designed to help clinicians effectively treat patients with Atrial Fibrillation through radiofrequency ablation.

A satellite symposium entitled ‘Improving the Full Range of AF Ablation Outcomes’ will provide attendees with insight about the value of using contact force technology in treating Atrial Fibrillation, whilst the Agora session ‘How to get better in Paroxysmal Atrial Fibrillation Ablation’ will introduce attendees to the latest technologies to reproduce and standardise ablation treatment. In addition, a Learning Village will provide physicians with the opportunity to improve the efficiency of Atrial Fibrillation ablations through practical and presentation-based sessions.